Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen.

Quotes for Scandion Oncology

Right Now

+/-
6.2
%
18,73%
Latest
39.3
High
40.4
Low
34
Volume
207 629
Turnover (SEK)
7 716 428
Value (MSEK)
842,0

Board

CEO

  • Bo Rode Hansen

Chairman Of The Board

  • Peter Høngaard

Board

  • Annie Rasmussen
  • Bo Hansen
  • Carl Borrebäck
  • Christian Vinding Thomsen
  • Jørgen Bardenfleth
  • Thomas Feldthus

Videos

Largest Owners

Name Capital % Votes % Date
Saniona AB 9,99 9,99 2020-07-31
Jan Stenvang 7,30 7,30 2020-03-31
Avanza Pension 5,71 5,71 2020-03-31
Nils Brünner 5,70 5,70 2020-10-01
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2020-11-19 Delårsrapport 2020-Q3